gilead glp-1 π¨ Market Shifts & Pharma Updates Ease your GLP Oral Small-Molecule GLP-1 Receptor Agonists:
Description
The first demonstration that DPP-4 inhibition reduces blood glucose levels in type 2 diabetes was published in 2002 [36]
Oral Market Dominance: despite the competition in injectables, Novo Nordisk retains a stronghold in the oral segment
Given all these unknowns, it may be best for Congress to pump the brakes on expanding GLP-1s in Medicare before we have a better understanding of their full value and a way to pay for it.
A thoughtful approach can help employees access care safely while helping employers manage rising healthcare costs and support long-term workforce well-being.
Rotate through the injection sites
